Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Hana Biosciences Charts. Click Here for more Hana Biosciences Charts.](/p.php?pid=staticchart&s=A%5EHBX&p=8&t=15)
Hana Biosciences (AMEX:HBX), a biopharmaceutical company
focused on advancing cancer care, will present at the 8th Annual BIO
CEO & Investor Conference, on Tuesday, February 14, 2006 at 3:00 PM
EST. The presentation will take place in the Basildon Room at the
Waldorf Astoria Hotel on 301 Park Avenue, New York, New York.
Mark Ahn, PhD, President and CEO of Hana Biosciences, will provide
a comprehensive company overview including an update on recent
corporate and scientific developments.
A live audio webcast of the presentation can be accessed on the
investor relations page of the company's website,
www.hanabiosciences.com. An audio replay of the presentation will also
be available for 90 days after the conference.
About Hana Biosciences
Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco,
CA-based biopharmaceutical company that acquires, develops, and
commercializes innovative products to advance cancer care. The company
is committed to creating value by building a world-class team,
accelerating the development of lead product candidates, expanding its
pipeline by being the alliance partner of choice, and nurturing a
unique company culture. Additional information on Hana Biosciences can
be found at www.hanabiosciences.com.
This press release contains forward-looking statements that
involve risks and uncertainties that could cause Hana's actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual outcomes
and results to differ materially from these statements. Among other
things, there can be no assurances that any of Hana's development
efforts relating to its product candidates will be successful. Other
risks that may affect forward-looking information contained in this
press release include the possibility of being unable to obtain
regulatory approval of Hana's product candidates, the risk that the
results of clinical trials may not support Hana's claims, Hana's
reliance on third party researchers to develop its product candidates
and its lack of experience in developing pharmaceutical products.
Additional risks are described in the company's Annual Report on Form
10-KSB for the year ended December 31, 2004. Hana assumes no
obligation to update these forward-looking statements, except as
required by law.